Advertisement
European Journal of Medical Physics
Advanced searchSave search
Letter to the Editor| Volume 96, P121-122, April 2022

Direct effect of the Directive Euratom 2013/59 on European hospitals hosting radionuclide therapies

DOI:https://doi.org/10.1016/j.ejmp.2022.03.004
Direct effect of the Directive Euratom 2013/59 on European hospitals hosting radionuclide therapies
Previous ArticleEuropean consensus on patient contact shielding
Next ArticleCorrigendum to “Investigation of bolus effect on skin dose in total body irradiations by helical tomotherapy” [Physica Medica 92 (2021) 84-85/OD 62]
      Radiotherapy involves irradiating tissue, often cancer cells, by irradiating this target with particles such as x rays, gamma rays, electrons, protons or ions. These particles interact with the tissue and produce by ionization free electrons and toxic free radicals proportionally to the energy imparted per unit of mass (named absorbed dose or shortly dose). Along their path, these particles produce by ionization toxic free radicals proportionally to the energy delivery per unit of mass (named dose). Irradiations are mainly performed in two ways. In external beam radiotherapy (EBRT), a medical device set outside the patient produces a particle beam that is focussed to the target. In brachytherapy sealed radiation sources are placed inside or close to the target, while in radionuclide therapy a vector labelled with a radionuclide is injected to the patient, the vector being designed to be preferably taken up by the target.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Physica Medica: European Journal of Medical Physics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf (accessed 2022 Feb 24).

        View in Article

      2. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2014:013:0001:0073:EN:PDF (accessed 2022 Feb 24).

        View in Article
        • Strigari L.
        • Konijnenberg M.
        • Chiesa C.
        • Bardies M.
        • Du Y.
        • Gleisner K.S.
        • et al.
        The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.
        Eur J Nucl Med Mol Imag. 2014; 41: 1976-1988
        View in Article
        • Cremonesi M.
        • Ferrari M.E.
        • Bodei L.
        • Chiesa C.
        • Sarnelli A.
        • Garibaldi C.
        • et al.
        Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.
        Eur J Nucl Med Mol Imag. 2018; 45: 2426-2441
        View in Article
        • Walrand S.
        • Jamar F.
        Renal and red marrow dosimetry in peptide receptor radionuclide therapy: 20 years of history and ahead.
        Int J Mol Sci. 2021; https://doi.org/10.3390/ijms22158326
        View in Article

      6. Chiesa C, Strigari L, Pacilio M, Richetta E, Cannatà V, Stasi M et al. Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). Physica Medica. 2021;89:317-26.

        View in Article
        • Flux G.
        • Buscombe J.
        BNMS position statement on molecular radiotherapy.
        Nucl Med Com. 2021; 42: 1061
        View in Article
        • Konijnenberg M.
        • Herrmann K.
        • Kobe C.
        • Verburg F.
        • Hindorf C.
        • Hustinx R.
        • et al.
        EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy.
        Eur J Nucl Med Mol Imag. 2021; 48: 67-72https://doi.org/10.1007/s00259-020-05038-9
        View in Article

      9. https://curia.europa.eu/juris/liste.jsf?language=en&T,F&num=148/78, para 22 ( accessed 2022 Feb 24).

        View in Article

      10. https://curia.europa.eu/juris/liste.jsf?language=en&num=C-62/00 (judgement para. 2) (accessed 2022 Feb 24).

        View in Article

      11. https://curia.europa.eu/juris/liste.jsf?num=C-188/89 (opinion 21, accessed 2022 Feb 24).

        View in Article
        • Bakhtina K.R.
        Farrell II and the concept of an ‘Emanation of the State’.
        Ind Intl Comp L Rev. 2018; 18: 241-248https://doi.org/10.2478/iclr-2018-0035
        View in Article

      13. https://curia.europa.eu/juris/liste.jsf?language=en&num=C-53/04 para 29. (accessed 2022 Feb 24).

        View in Article

      14. https://curia.europa.eu/juris/liste.jsf?language=en&num=C-413/15 para 35 (accessed 2022 Feb 24).

        View in Article
        • Chiesa C.
        • Sjogreen Gleisner K.
        • Flux G.
        • Gear J.
        • Walrand S.
        • Bacher K.
        • et al.
        The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.
        Eur J Nucl Med Mol Imaging. 2017; 44: 1783-1786
        View in Article

      16. https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A32001L0083 (accessed 2022 Feb 24).

        View in Article

      17. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A31984L0466 (accessed 2022 Feb 24).

        View in Article

      18. https://eur-lex.europa.eu/eli/dir/1997/43/oj (accessed 2022 Feb 24).

        View in Article

      19. https://www.ema.europa.eu/en (accessed 2022 Feb 24).

        View in Article

      20. https://curia.europa.eu/juris/document/document.jsf?docid=140965&doclang=EN (accessed 2022 Feb 24).

        View in Article

      21. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:52013SC0349 (point 363. art. 59, accessed 2022 Feb 24).

        View in Article

      Article info

      Publication history

      Accepted: March 4, 2022
      Received in revised form: February 24, 2022
      Received: October 15, 2021

      Identification

      DOI: https://doi.org/10.1016/j.ejmp.2022.03.004

      Copyright

      © 2022 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX